Latest Royalty Income News

Atomic Eagle Limited has announced a substantial uranium exploration target at its Muntanga Project in Zambia, supported by promising drilling results that suggest significant resource expansion potential.

Red Hill Minerals reported a solid $7.8 million royalty from its Onslow Iron Project and unveiled promising exploration results across its Broken Hill and Anabama projects, reinforcing its growth trajectory.

Anagenics Limited reports a significant turnaround with profitable trading in the second quarter of FY26, driven by strong brand performance and a successful capital raise. The company is poised for growth with expanding product lines and international ambitions.

Pearl Gull Iron Limited has completed the sale of its Cockatoo Island Project, receiving $2.5 million upfront and securing a 4% indirect equity stake in Crestlink Pty Ltd, alongside future royalties. The company is now focused on leveraging these proceeds to explore new opportunities.

Gullewa Limited has increased its joint venture interest to 98.4%, initiated diamond drilling at its South Darlot Gold Project, and appointed a seasoned mining executive to its board, signalling a strategic push forward.

GWR Group Limited reports a robust cash position of $75 million and progresses its Prospect Ridge Magnesite Project alongside strategic investments in tungsten and royalties from iron ore and gold assets.

Juno Minerals has finalised the sale of its Mount Mason DSO Hematite Project for A$6 million plus royalties, while advancing exploration at its flagship Mount Ida Magnetite Project with promising gold assay results and planned drilling.

Fitzroy River Corporation reported steady royalty income for the December 2025 quarter, while advancing key projects including a $40 million funding campaign for the Rafael Gas Project and a $150 million equity raise for Snowy River Gold development.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Juno Minerals has reported significant gold assay results from rock chip channel sampling at its Mount Ida project, with values up to 6.60 g/t Au. These findings pave the way for a planned shallow drilling program to explore vein extensions.

Neuren Pharmaceuticals reported a milestone quarter with DAYBUE net sales reaching US$101.1 million, driving a 24% jump in royalty income. The expanding patient base and community physician uptake signal strong growth ahead.